Pharmaceutical Executive Daily: New Research on Ozempic
Today's Pharmaceutical Executive Daily covers key news in the pharmaceutical and life sciences industry, including the FDA approval of Bayer's Lynkuet and new research on Ozempic.
FDA Approval of Bayer's Lynkuet
The FDA has approved Bayer's Lynkuet (elinzanetant) for treating moderate to severe vasomotor symptoms associated with menopause.
- Lynkuet is the first dual neurokinin 1 and 3 receptor antagonist.
- Approval is based on Phase III OASIS trial data showing significant reductions in hot flash frequency and severity.
Lynkuet provides a non-hormonal therapeutic alternative for patients seeking relief from menopausal symptoms without estrogen exposure.
Author's summary: Ozempic may reduce biological age.
More News
- Hudson’s Bay Stripes Return at Canadian Tire in Limited Capsule
- Joe Perry Sheds New Light on the Future of Aerosmith
- Irving Berlin - Overview
- Hudson Couteau de table en acier
- Brasero Extérieur RedFire Irving medium black
- Hunt: Showdown Elaborates On Upcoming Player Profiles In Update 2.6
- Hudson’s Bay Downtown Vancouver Store for Sale
- Semi-truck driver shot on I-55 in Jefferson County, suspect charged
- Rural road repair 'wish list' for the Sunshine Coast drawn up
- What Mavericks’ Anthony Davis said after getting shut down by Thunder